Content area

Abstract

Tarsus Pharmaceuticals Inc (TARS) - Pharmaceuticals and Healthcare Product Pipeline

Summary

Tarsus Pharmaceuticals Inc (Tarsus Pharmaceuticals) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics. The company’s pipeline products include TP-03, TP-04 and TP-05. Its pipeline treats meibomian gland disease, rosacea disease, lyme disease and malaria. Tarsus Pharmaceuticals also carries out Xdemvy for the treatment of demodex blepharitis, an eyelid margin disease characterized by inflammation, redness and ocular irritation.

This report provides outline on pipeline products by Number of Pipeline Products by Therapy Area, Indication, development stage and Partnered/Out-Licensed Products.

This report is built using information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Details

1007133
Company / organization
Title
Tarsus Pharmaceuticals Inc (TARS)
Publication title
Number of pages
75
Publication year
2025
Publication date
2025
Publisher
GlobalData plc
Place of publication
London
Country of publication
United Kingdom
Publication subject
Source type
Report
Language of publication
English
Document type
Company Profile
Document feature
Tables; Graphs; Company description; Company financials; Company competitors; Company SWOT
ProQuest document ID
2792776760
Document URL
https://www.proquest.com/reports/tarsus-pharmaceuticals-inc-tars/docview/2792776760/se-2?accountid=208611
Copyright
Copyright GlobalData plc 2025
Last updated
2025-08-29
Database
ProQuest One Academic